cyclophosphamide rheum
Selected indexed studies
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (Ann Rheum Dis, 2024) [PMID:36927642]
- Update οn the diagnosis and management of systemic lupus erythematosus. (Ann Rheum Dis, 2021) [PMID:33051219]
- Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. (Ann Rheum Dis, 2012) [PMID:22128076]
_Worker-drafted node — pending editorial review._
Connections
cyclophosphamide rheum is a side effect of
Sources
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. (2024) pubmed
- Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. (2023) pubmed
- Update οn the diagnosis and management of systemic lupus erythematosus. (2021) pubmed
- Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. (2002) pubmed
- Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. (2012) pubmed
- Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis. (2025) pubmed
- Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review. (2021) pubmed
- Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis. (2025) pubmed
- Vasculitis and Pregnancy. (2017) pubmed
- Microscopic polyangiitis. (2010) pubmed